Participants' global self‐assessment of acne improvement Good or very good improvement (long term: treatment duration > 8 weeks) · participants with acne
Azelaic acid showed no clear difference in participants' global self‐assessment of acne improvement Good or… compared with clindamycin (low certainty).
1 finding from 1 review
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · people undergoing initial treatment for KD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · people with active UC
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Participant's global self‐assessment of improvement (long‐term data) ‐ not measured · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review